Bavarian Nordic AS (OCSE:BAVA) is set to release its Q3 2024 earnings on Nov 15, 2024. The consensus estimate for Q3 2024 ...

Pregnant women and infants are at risk should they contract mpox but there are no approved vaccines for this population.

Bavarian Nordic gets $63 million US government order for small pox, mpox vaccine September 24, 2024 Future of Healthcategory Bavarian says mpox vaccine approved by EU regulator for adolescents ...

UK Secures Additional Doses Of Bavarian Nordic Mpox Vaccine To Combat New Variant Threat The UK government has purchased 150,000 mpox vaccine doses from Bavarian Nordic, enhancing its response to ...

The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The World Health Organisation has okayed Bavarian Nordic's mpox vaccine for young persons, aged between 12 and 17, as they are particularly believed to be vulnerable to outbreaks of the viral ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...